Randomized Configuration Targeted Integration for Cell Line Development

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional strategies for developing commercial cell lines for recombinant protein production, such as monoclonal antibodies and bispecific antibodies, are resource-intensive and time-consuming, particularly when trying to achieve optimal expression levels and product quality attributes, as they often require extensive screening of clones and can be unstable or suboptimal in arrangement and copy numbers of transgenes.

Innovation Solution

The Randomized Configuration Targeted Integration (RCTI) method, which involves generating a library of host cells by contacting them with vectors containing sequences of interest, introducing these sequences into the cells, and selecting for specific cellular or product attributes, allowing for high-throughput screening with fewer resources while maintaining expression levels and product quality comparable to conventional methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If random integration methods are used to generate cell lines, then different clones with different compositions and ratios of transgenes can be obtained, but extensive screening of hundreds or thousands of clones is required which is time-consuming and resource-intensive

Engineering Contradiction:
Improve多样性 of transgene compositionsVSAvoidscreening time
Core Design Contradiction:
Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-establishing a library of host cells with predetermined transgene arrangements and copy numbers through targeted integration at specific genomic loci. This eliminates the need for extensive screening because the desired transgene configurations are already present in the library before screening begins, directly resolving the contradiction between obtaining diverse transgene compositions and reducing screening time.

Inventive Principle:
Principle #10Preliminary action

2Manufacturing precision

If targeted integration approaches are used to control transgene arrangement and copy numbers, then more control is achieved, but the possibility of generating random combinations and ratios of different transgenes is minimized requiring multiple individual tests

Engineering Contradiction:
Improvecontrol over transgene arrangementVSAvoidcell line development workload
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies universality by creating a single comprehensive library that encompasses multiple transgene arrangements and copy number configurations simultaneously. Rather than performing multiple separate targeted integration experiments, the library serves as a universal resource containing all desired variations, allowing researchers to screen for optimal configurations without repeating the integration process multiple times.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If conventional strategies are used to achieve optimal expression levels and product quality, then desirable performance can be obtained, but extensive screening of clones is required making the process resource-intensive

Engineering Contradiction:
Improveproduct quality attributesVSAvoidresources consumed
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by pre-establishing a library of host cells with predetermined transgene arrangements and copy numbers through targeted integration at specific genomic loci. This eliminates the need for extensive screening because the desired transgene configurations are already present in the library before screening begins, directly resolving the contradiction between obtaining diverse transgene compositions and reducing screening time.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS20230279583A1Randomized configuration targeted integration of nucleic acids
Publication Date: 2023.09.07 GENENTECH INC
  • US20230279583A1 patent drawing
  • US20230279583A1 patent drawing
  • US20230279583A1 patent drawing

AI summary

The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.